ARWR following the exact path of BMRN
A: Strengthen =0
B: Weaken =6
C: No Effect =10
One member had to leave and did not vote.
Exon 51) affects around 13-15 percent of the 15,000 or so people with the disease in the U.S. That mutation prevents the production of dystrophin, a protein needed for correct muscle formation. BMRN claims their drugs allows the body to create enough dystrophin to change the disease
"The mechanism is strikingly targeted. It only does one thing. If it doesn’t do that thing, that would make you wonder
This is not new, only reworded: old wording were:
“We are already beginning to see early signs of immune recovery in some of the treated patients we are watching very closely that space to see what will be the final outcome......